To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
July 10, 2007
In the July issue of the prestigious journal Cancer Cell, David A. Guertin, PhD (Damon Runyon Fellow '03-'06) reviews recent progress in defining the mTOR pathway, a critical signaling system with growing relevance to cancer. For example, the drug rapamycin, which inhibits mTOR, is currently in clinical trials for a variety of tumor types. Dr. Guertin and his mentor, Dr. David Sabatini, have made seminal contributions to understanding how the mTOR pathway is deregulated in human cancers.